Journal article
Phase II Trial of Remitogen™ (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma
Clinical lymphoma, Vol.2(3), pp.188-190
12/2001
DOI: 10.3816/CLM.2001.n.026
PMID: 11779298
Abstract
no abstract
Details
- Title: Subtitle
- Phase II Trial of Remitogen™ (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma
- Creators
- Kevin S Brown - Division of Hematology, Oncology, and Blood and Marrow Transplant, Department of Internal Medicine and Holden Comprehensive Cancer Center, University of Iowa, Iowa CityDaniel J Levitt - Protein Design Labs, Fremont, CaliforniaMary Shannon - Holden Comprehensive Cancer Center, University of Iowa, Iowa CityBrian K Link - Division of Hematology, Oncology, and Blood and Marrow Transplant, Department of Internal Medicine and Holden Comprehensive Cancer Center, University of Iowa, Iowa City
- Resource Type
- Journal article
- Publication Details
- Clinical lymphoma, Vol.2(3), pp.188-190
- DOI
- 10.3816/CLM.2001.n.026
- PMID
- 11779298
- ISSN
- 1526-9655
- eISSN
- 2331-4486
- Language
- English
- Date published
- 12/2001
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094736302771
Metrics
15 Record Views